GenMark Diagnostics Stock News

CARLSBAD, Calif., April 22, 2020 -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Ar

GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Brian Andrew Mitchell sold 8,000 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $8.00,

GenMark Diagnostics (NASDAQ:GNMK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.co

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alnylam Pharmaceuticals,...

On Tuesday, 27 stocks hit new 52-week highs. Highlights: The largest company by market cap to set a new 52-week high was Vertex Pharmaceuticals (NASDAQ: VRTX). The...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) Abbott Laboratories (NYSE...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) Abbott Laboratories (NYSE...

On Monday, 38 companies hit new 52-week highs. Things to Consider: The largest company by market cap to hit a new 52-week high was Walmart (NYSE: WMT). The company with...

Selbyville, Delaware, April 20, 2020 -- Global Market Insights, Inc. has recently added a new report on COVID-19 detection kits market which estimates the global market.

How far off is GenMark Diagnostics, Inc. (NASDAQ:GNMK) from its intrinsic value? Using the most recent financial data...

GenMark Diagnostics (NASDAQ:GNMK) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, BidAskClub reports. Other analysts also rec

GenMark Diagnostics (NASDAQ:GNMK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday, Zacks.com reports. The firm currently ha